BioSpace News Archive

Deals

Therma Bright Announces Amendments to InStatin & InVixa Acquisitions

InStatin & InVixa Are Developing Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)

September 27, 2023

·

3 min read

BioForest

LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration

LumiThera Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI) of up to $2.3M in funding over two years.

September 27, 2023

·

3 min read

EnCompass receives FDA conditional IDE approval to commence a US pilot study of its F2 cerebral embolic protection (CEP) system in patients undergoing transcatheter aortic valve replacement (TAVR)

EnCompass Technologies, Inc. announced the US Food and Drug Administration (FDA) officially granted conditional Investigational Device Exemption (IDE) approval for its F2 cerebral embolic protection system on Friday, September 22, 2023.

September 27, 2023

·

3 min read

Pharm Country

Blocking Abnormal Stem Cell Signal during Aging Lessens Related Bone Loss

A cellular signal essential to the development of the skeleton increases during aging to weaken bones, finds a new study in mice.

September 27, 2023

·

4 min read

BioMidwest

Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development

Evozyne announced the closing of an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development.

September 27, 2023

·

2 min read

Drug Development

Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual MeetingFour-year Analysis of C-144-01 Trial Cohorts 2 and 4

Iovance Biotherapeutics, Inc. announced poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte therapies at the Society for Immunotherapy of Cancer’s 38th Annual Meeting in San Diego, CA, November 1-5, 2023.

September 27, 2023

·

5 min read

Business

McKesson Corporation Announces Second Quarter Fiscal 2024 Earnings Release Date

McKesson Corporation will release its second quarter fiscal 2024 financial results after market close on Wednesday, November 1, 2023.

September 27, 2023

·

1 min read

Genetown

PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology

PepGen Inc. announced that it will be presenting at the 28th Annual Congress of the World Muscle Society, being held October 3-7 in Charleston, South Carolina.

September 27, 2023

·

4 min read

Policy

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda announced that the U.S. Food and Drug Administration has approved a subcutaneous administration of ENTYVIO® for maintenance therapy in adults with moderately to severely active ulcerative colitis after induction therapy with ENTYVIO intravenous.1 ENTYVIO SC is expected to be available in the U.S. as a single-dose pre-filled pen by the end of October.

September 27, 2023

·

15 min read

Business

Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023

Aytu BioPharma, Inc.announced financial and operational results for the fourth quarter and fiscal year ended June 30, 2023.

September 27, 2023

·

19 min read